Cytodigm

Cytodigm is a biotechnology company with a pipeline of innovative non-viral drug delivery systems (DDS). These nanoparticle platform technologies support internal/co-development projects, as well as projects where Cytodigm out-licenses the DDS technology to external biopharmaceutical companies to support their Clinical Trials. The Cytodigm IP portfolio focuses on the compositions, methods of use, and manufacturing of DDS technologies. This includes 7 Granted Patents and 13 PCTs. Lead Nanoparticle Technologies: 1. Zetafinity (PNP) - A polymeric nanoparticle made of the polymer poly(lactic-co-glycolic) acid (PLGA). Currently in Takeda Phase 2 Clinical Trials. Licensing available for Oncology indicacations. 2. Cytofinity (LNP) - A lipid nanoparticle (LNP) incorporating a natural lipid-ganglioside as part of the formulation. What is unique about this formulation is that a ganglioside replaces the Polyethylene Glycol (PEG)-lipid. Further differentiations from other nanocarriers: (1) No need for a PEG-lipid, (2) Active Cell Targeting, (3) LNPs themselves are Anti-Inflammatory, and (4) Cytofinity LNPs remain intact after nebulization and can transfect the lungs. Cytodigm was founded in 2022 by Bin Wu, Ph.D. and is located in Boston, Massachusetts. He has over 20 years' of experience in biodegradable lipid nanoparticles (LNP), polymer nanoparticles (PNP), lipoplexes, and polymeric microparticles for the targeted delivery of nucleic acids, peptides, proteins, and small molecules. He is the inventor of over 20 US Patents and 30 International PCT Applications. Bin earned a Ph.D. in Polymer Chemistry from the University of Massachusetts Amherst. Cytodigm is supported by strong partnerships, scientists, and consultants that are strong players in the cell & gene therapy (CGT) space, both academia and industry. For inquiries, please reach out to info@cytodigm.com